バイオサイトジェンは患者様の必要を満たす創造的な抗体医薬品の開発に尽力しています。腫瘍、自己免疫、代謝、抗感染症など複数の疾患分野に特化し、独自の医薬品開発手法を十分に活用することにより、モノクローナル抗体、二重特異性抗体、抗体薬物複合体(ADC)など10を超える複数の開発パイプラインを有するに至りました。私たちは臨床開発チームと豊かな臨床リソースを駆使し、パイプラインの開発を推し進め、医薬品の臨床試験プロセスの加速を目指しています。
臨床段階パイプライン
Investigator Initiated Trials
More
Pancreatic ductal adenocarcinoma (1L&2L)
More
臨床段階パイプライン
Oncology
Indication(s):
Solid tumors
Preclinical
IND
Phase l
Phase ll
Phase III
Indication(s):
Solid tumors
Preclinical
IND
Phase l
Phase ll
Phase III
Mono/Combo Therapy:
YH003+YH001
Indication(s):
Intratumoral injection
Preclinical
IND
Phase l
Phase ll
Phase III
Mono/Combo Therapy:
PD-1+ chemo
Indication(s):
Pancreatic ductal adenocarcinoma (1L&2L)
Preclinical
IND
Phase l
Phase ll
Phase III
Mono/Combo Therapy:
PD-1+ chemo
Indication(s):
Mucosal melanoma
Preclinical
IND
Phase l
Phase ll
Phase III
Mono/Combo Therapy:
PD-1+ YH001
Indication(s):
Solid tumors
Preclinical
IND
Phase l
Phase ll
Phase III
Indication(s):
Solid tumors
Preclinical
IND
Phase l
Phase ll
Phase III
Indication(s):
Solid tumors
Preclinical
IND
Phase l
Phase ll
Phase III
Partner:
Chipscreen NewWay
臨床前パイプライン
Inflammation and Autoimmunity
臨床前パイプライン
Oncology
Indication(s):
Solid tumors
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
![](/Public/static/images/default.jpg)
Radiance
Indication(s):
Solid tumors
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
![](/Public/static/images/default.jpg)
DOMA
Molecular Format:
Undisclosed
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Rights:
![](/Public/static/images/default.jpg)
Global
Inflammation and Autoimmunity
Target(s):
CD40 inhibitor
Indication(s):
Autoimmunity
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Rights:
![](/Public/static/images/default.jpg)
Global
Molecular Format:
Undisclosed
Indication(s):
Autoimmunity
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Rights:
![](/Public/static/images/default.jpg)
Global
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
![](/Public/static/images/default.jpg)
Dragonboatbio
Rights:
![](/Public/static/images/default.jpg)
Global
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
![](/Public/static/images/default.jpg)
Undisclosed
Rights:
![](/Public/static/images/default.jpg)
ex-Greater China
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
![](/Public/static/images/default.jpg)
DOMA
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
![](/Public/static/images/default.jpg)
DOMA
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
![](/Public/static/images/default.jpg)
LiberoThera
Rights:
![](/Public/static/images/default.jpg)
Global
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
![](/Public/static/images/default.jpg)
Undisclosed
Rights:
![](/Public/static/images/default.jpg)
Global
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
![](/Public/static/images/default.jpg)
Undisclosed
Rights:
![](/Public/static/images/default.jpg)
ex-Greater China
Target(s):
WT1/HLA-A02×CD3×4-1BB
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
![](/Public/static/images/default.jpg)
Undisclosed
Rights:
![](/Public/static/images/default.jpg)
Global
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
![](/Public/static/images/default.jpg)
DOMA
Infectious Diseases
Indication(s):
Infectious diseases
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
![](/Public/static/images/default.jpg)
Undisclosed
Rights:
![](/Public/static/images/default.jpg)
ex-Greater China
Rare Diseases
Indication(s):
Rare diseases
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
![](/Public/static/images/default.jpg)
Undisclosed
Rights:
![](/Public/static/images/default.jpg)
ex-Greater China